Pharmacotherapy of neuropsychiatric symptoms: opportunities, challenges and current prospects
Peter V Rabins and Constantine G Lyketsos
This article has no abstract so we have provided the first paragraph of the full text.
Neuropsychiatric symptoms (NPS) are highly prevalent in diseases characterized by CNS pathology, and are a major source of disability, cost and carer burden. For example, one study has shown that 60% of patients with Alzheimer's disease (AD) in a community-based sample experienced NPS during a 1-month period [Lyketsos CG et al. (2002) JAMA 288: 1475–1483], and over 80% experienced NPS during the course of their illness.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.